What are the most coveted pipeline assets and which companies have the most
valuable launch portfolios?
Which Big Pharma companies have the largest late-stage pipelines?
How does therapy area concentration for Big Pharma compare to the rest of the
industry?
How is Big Pharma concentrated in regards to therapy area in late-stage assets?
Strategy analysis
How is Big Pharma using licensing deals to propel growth and in what therapy areas
are deals concentrated?
How is Big Pharma capitalizing on immuno-oncology using M&A and dealmaking?
Can data transform pharmaceutical R&D to maintain a supply of innovative
treatments?
From R&D investment to externalization: where is Big Pharma maximizing value?
Highlights
Big Pharma prescription drug sales are forecast to grow to $351bn by 2026 at a
compound annual growth rate of 0.8%
Number one company in 2021: Pfizer sustains top ranking in prescription drug sales
out to 2021
Number one company in 2026: Roche out-performs Pfizer out to 2026
Pharmavitae Index: Roche tops the index with a score calculated from 9 different
metrics based on portfolios sales, pipelines, growth prospects and financials
Most valuable product: Keytruda will become the highest selling product with global
sales forecast at $9bn
Most lucrative therapy area: Oncology will maintain the largest proportion of Big
Pharma prescription sales out to 2026.
Most valuable class: PD-1/PD-L1 inhibitors will continue to build momentum out to
2026
Pipeline launch analysis: Big Pharma’s launch portfolio is set to add $58.3bn in
revenues out to 2026
Ask to Expertise @
https://www.reportsworldwide.com/enquiry?report_id=41337
Report Contents
EXECUTIVE SUMMARY
Big Pharma Outlook 2026
Analyst Outlook
Revenue Analysis
Global prescription pharmaceutical revenue overview
Company performance ranking
Regional overview
Top class overview
Blockbuster tracker
Top 30 products in 2026